FDA Biosimilars (351(k) Pathway)

The FDA biosimilar (351(k)) pathway is the abbreviated licensure route Congress created for biological products that are demonstrated to be highly similar to, and to have no clinically meaningful differences from, an already-licensed reference biological product. It sits alongside — and depends on the prior existence of — the standard 351(a) BLA pathway (the cover form for either route is FDA Form 356h), and it is administered under different statutory authority than the small-molecule generic-drug (ANDA) system.

Statutory basis: the BPCIA

Section 351(k) of the Public Health Service Act was added by the Biologics Price Competition and Innovation Act (BPCIA), enacted March 23, 2010 as part of the Affordable Care Act. The BPCIA created a licensure pathway specifically for biosimilar and interchangeable biological products, modeled conceptually on the Hatch-Waxman abbreviated pathway for generic drugs but built around biosimilarity rather than bioequivalence, since biologics are manufactured in living systems and cannot be reproduced as exact chemical copies the way small-molecule generics can.

The core standard: “highly similar” and “no clinically meaningful differences”

To be licensed as a biosimilar, a sponsor must show that its proposed product is highly similar to a single FDA-licensed reference product notwithstanding minor differences in clinically inactive components, and that there are no clinically meaningful differences between the two products in terms of safety, purity, and potency. This is a comparative standard, not an independent efficacy standard — the sponsor is not required to independently re-establish that the biological mechanism works in the target condition (the reference product already established that); the burden is to show the biosimilar behaves the same way as a product FDA has already found safe and effective.

Totality-of-evidence, stepwise approach

FDA evaluates biosimilarity using a stepwise, totality-of-the-evidence framework rather than requiring any single study type to carry the full weight of the determination. The foundation is extensive analytical (structural and functional) characterization comparing the proposed biosimilar to the reference product at the molecular level; sponsors then layer in animal data where scientifically relevant, human pharmacokinetic/pharmacodynamic comparison, and immunogenicity assessment. A comparative clinical efficacy trial is added only to address residual uncertainty that the analytical and PK/PD data could not resolve — it is the last, not the first, piece of evidence FDA looks to, which is why the biosimilar pathway is meaningfully faster and less costly than a standalone IND-supported 351(a) program.

Interchangeability: a higher, separate designation

Biosimilarity and interchangeability are not the same determination. A product can be a licensed biosimilar without being interchangeable (as Zarxio was for years). Interchangeable status is an additional designation that allows a pharmacist to substitute the biosimilar for the reference product at the pharmacy counter without requiring the prescriber to authorize the switch each time — the pharmacy-level equivalent of automatic generic substitution — subject to the pharmacy-substitution laws of the state where the dispensing occurs. Historically, sponsors were expected to support an interchangeability claim with dedicated switching-study data (showing no increased risk from alternating between the biosimilar and reference product). Draft FDA guidance issued in 2024 proposed removing that expectation in most cases, indicating interchangeability can often be supported using the same comparative analytical and clinical data already generated to establish biosimilarity — sponsors and reviewers should confirm the current, finalized status of that guidance before relying on it, since it was still in draft form as of this writing.

Distinct from the ANDA generic-drug pathway

Because biologics are produced in living cells rather than synthesized chemically, no biosimilar is ever an exact molecular replica of its reference product the way a small-molecule generic is of its reference listed drug — batch-to-batch variability exists even within a single manufacturer’s own reference product. This is precisely why the 351(k) standard is comparative similarity plus no clinically meaningful difference, rather than the bioequivalence standard ANDA generics must meet under the Hatch-Waxman framework. The two pathways sit under different parts of federal law (PHS Act 351(k) vs. FD&C Act Hatch-Waxman provisions), are reviewed against different technical standards, and should not be conflated when describing a product’s regulatory basis.

Reference product exclusivity

The BPCIA also grants the reference product’s sponsor a period of regulatory exclusivity — commonly cited as 12 years from the reference product’s first licensure — during which FDA may not approve a competing 351(k) biosimilar application referencing it, separate from any patent protection the reference product may separately hold. If FDA ultimately declines to approve a 351(k) application after review, it issues a Complete Response Letter, the same non-approval mechanism used across NDA, ANDA, and BLA applications.

Which FDA center reviews biosimilar applications

Most biosimilars — including monoclonal antibodies and insulin products — are reviewed by CDER’s Office of Therapeutic Biologics and Biosimilars, reflecting a 2003 transfer of therapeutic protein product review from the Center for Biologics Evaluation and Research (CBER) to CDER. CBER continues to review biosimilars of vaccines, blood products, and other product classes that remain within its jurisdiction.

Frequently asked questions

Is a biosimilar the same as a generic drug?

No. A generic is a chemically identical copy of a small-molecule drug, approved via ANDA on a bioequivalence standard. A biosimilar is a highly similar, but not identical, version of a large, complex biological product, approved via 351(k) on a biosimilarity standard because exact replication is not scientifically possible for products manufactured in living systems.

Does a biosimilar need its own clinical trials proving it works?

Not a full independent efficacy program. The sponsor leverages the reference product’s established safety and efficacy record and instead generates comparative data — analytical, PK/PD, and, where residual uncertainty remains, comparative clinical data — showing the biosimilar behaves the same as the reference product.

Can any biosimilar be substituted at the pharmacy without asking the prescriber?

Only if it holds the separate interchangeable designation, and only where the pharmacy-substitution laws of that state permit it. A biosimilar that is not designated interchangeable cannot be automatically substituted this way, even though it is fully FDA-licensed.